BenevolentAI Investor Conference Presentation Deck
Benevolent PlatformTM drives our three revenue streams
A versatile, scalable and robust Al-enabled drug discovery platform built with expert scientists, leveraging
multi-modal data foundations
Benevolent
Platform™
End-to-End Drug
Discovery
Drug discovery offerings
ESTABLISHED BUSINESS
Platform enables novel discoveries
throughout the drug discovery
process
Continuing to expand on our
industry-leading collaborations
Validated by collaborations with
AstraZeneca and Merck
High value collaborations
Upfront payments + milestones
+ royalties
Preclinical & Clinical
Development Pipeline
Platform generated assets
5 high potential assets
Potentially first-in-class or
best-in-class assets providing novel
therapeutic opportunities
Progressing assets to significant
inflection points
Mid-long term value creation
Upfront fees + milestones + royalties
BenevolentAl Proprietary
db
NEW EXPANSION OPPORTUNITIES
3D
Knowledge
Exploration Tools
New customisable SaaS products
Suite of Al products that surface
data, perform analysis, and give
scientific recommendations
BenAl-Q and BenAl Research
Assistant products enabling
enhanced decision making
Building from our core technologies
to develop innovative ways to serve
customers and their scientists
Highly scalable, recurring revenue
Fees for Setup, Platform licenses & Seats +
Ongoing support services
Benevolent
3View entire presentation